Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia

Biochemical Pharmacology(2017)10.1016/j.bcp.2017.01.002Source: DataRank Database

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia is a research paper published in Biochemical Pharmacology (2017). On theSindex it has a DataRank of 0.666. It has been cited 84 times.

N/A

0.666DataRank · unranked

Scored on demand from live citation data

84 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 5.34)OA: closedTopics (69)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.666

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Nuy Chau,Andrew Rowland ORCID,Kushari Burns,Ross A. McKinnon ORCID,Peter I. Mackenzie

Live enrichment

PubMed:28065859 OpenAlex:https://openalex.org/W2567935285

National Health and Medical Research Council of Australia

Grant: 1044063

FWCI

5.34

Citation Percentile

1.0%

Citation Trend

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

closedLicense: https://www.elsevier.com/tdm/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S0006295217300023?httpAccept=text/plain

publisherhttps://api.elsevier.com/content/article/PII:S0006295217300023?httpAccept=text/xml

journalhttps://doi.org/10.1016/j.bcp.2017.01.002

repositoryhttps://pubmed.ncbi.nlm.nih.gov/28065859

Fields of Study

Chronic Lymphocytic Leukemia ResearchBiochemical and Molecular ResearchHIV/AIDS drug development and treatmentBilirubinCatalysisEnzyme InhibitorsGlucuronosyltransferaseHumansHyperbilirubinemiaIndazolesKineticsLapatinibMicrosomes, LiverNiacinamidePhenylurea CompoundsPyridinesPyrimidinesQuinazolinesSorafenibSulfonamides

MeSH Terms

SorafenibLapatinibBilirubinCatalysisEnzyme InhibitorsHumansHyperbilirubinemiaIndazolesKineticsMicrosomes, LiverNiacinamidePhenylurea CompoundsPyridinesPyrimidinesQuinazolinesSulfonamidesGlucuronosyltransferase

Keywords

GlucuronidationGlucuronosyltransferaseLapatinibRegorafenibPharmacologyEnzymeChemistryBilirubinSorafenibMicrosomeIC50Internal medicineBiochemistryMedicineHepatocellular carcinomaIn vitroCancerColorectal cancerTrastuzumabHyperbilirubinemiaEnzyme inhibitionUDP-glucuronosyltransferaseKinase InhibitorsDrug–drug InteractionLapatinib (Pubchem Cid: 208908)Propofol (Pubchem Cid: 4943)Pazopanib (Pubchem Cid: 10113978)Sorafenib (Pubchem Cid: 216239)Bilirubin (Pubchem Cid: 5280352)Drug–endobiotic InteractionRegorafenib (Pubchem Cid: 178102514)Β-estradiol (Pubchem Cid: 5757)

Sustainable Development Goals

SDG 0: Good health and well-being

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia

FAIR Checklist

DataRank Breakdown

Authors (9)

Funding (1 grants)

Impact

Open Access

Topics